Overview

Zalutumumab in Head and Neck Cancer

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Treatments:
Antibodies, Monoclonal
Zalutumumab